Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis

Early Intervention in Psychiatry

Volumn 3, Issue 1, 2009, Pages 28-34

  Phillips, Lisa J ^a   Cotton, Sue ^a,b   Mihalopoulos, Cathrine ^c   Shih, Sophy ^c   Yung, Alison R ^a,b   Carter, Rob ^c   McGorry, Patrick D ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ORYGEN RESEARCH CENTRE   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Cost analysis; Prevention; Psychotic disorder; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE NEED; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; ONSET AGE; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOTHERAPY;

ANTIPSYCHOTIC AGENTS; COST SAVINGS; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COSTS; HUMANS; INPATIENTS; MALE; OUTPATIENTS; PSYCHOTHERAPY; PSYCHOTIC DISORDERS; RISK FACTORS; YOUNG ADULT;

EID: 64949192179     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2008.00106.x     Document Type: Article

References (18)

1. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921-8.
2. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-9.
3. Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Br J Psychiatry 2004; 185: 291-7.
4. McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: Detection and treatment of the first episode and the critical early stages. Med J Australia 2007; 187: S8-10.
5. Mihalopolous C, McGorry PD, Carter RC. Is early intervention in first episode psychosis an economically viable method of improving outcome? Acta Psychiatr Scand 1999; 54: 1-9.
6. Yung AR, Phillips LJ, McGorry PD. Treating Schizophrenia in the Prodromal Phase. London: Taylor & Francis, 2004.
7. Phillips LJ, McGorry PD, Yuen HP et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 2007; 96: 25-33.
8. Yung AR, Yuen HP, McGorry PD et al. Mapping the onset of psychosis: The Comprehensive Assessment of At Risk Mental States (CAARMS). Aust N Z J Psychiatry 2005; 39: 964-71.
9. Yung AR, Phillips LJ, Yuen HP et al. Psychosis prediction: 12 month follow-up of a high risk ('prodromal') group. Schizophr Res 2003; 60: 21-32.
10. Australian Institute of Health and Welfare. Health Expenditure Australia 2001-2002. 2003, cat. no. HWE 24. Canberra: AIHW, 2003.
11. Gold M, Siegel J, Russell L et al. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
12. Burgess P, Buckingham B. Monitoring Value for Money in Mental Health Services. Melbourne: Mental Health Research Institute, 1999.
13. Mihalopoulos C, Meadows G, Stiller A et al. Attaching unit costs to Australia's National Survey of Mental Health and Wellbeing. J Ment Health Policy Econ 2005; 8: 61-9.
14. Department of Health and Aging. Schedule of Pharmaceutical Benefits. Canberra: Commonwealth of Australia, 2002.
15. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197-200.
16. Barber JA, Thompson SG. Analysis of cost data in randomised trials: An application of the non-parametric bootstrap. Statistics Med 2000; 19: 3219-36.
17. Heinrichs DW, Hanlon TE, Carpenter WJ. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388-98.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Text Revision, 4th edn. Washington, DC: American Psychiatric Association, 2000.